Commercial cancer cell lines have long been extensively used as an important platform to study cancer. They have contributed to a plethora of discoveries in the field of cancer research. However, there are limitations with using these cell lines, such as induced mutations over the long-term in vitro culture. These mutations cause incorrect exhibition of the in vivo characteristics of the cancer cells. Here, we focused on establishing Patient-derived breast cancer cell lines and attempted to characterize them in terms of several biomarkers that are shown to be overexpressed in breast cancer cells. Patient-derived breast cancer cell lines are more reliable tools to study the molecular and cellular processes taking place in vivo, since they are freshly isolated from the tumor biopsy and do not undergo induced immortalization. We explored the CK19, Ki67, vimentin, EpCAM, E-cadherin, and N-cadherin expression in three successfully established patient-derived breast cancer cell lines
